Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients

Mohamed-Yacine Khitri(Sorbonne Université), Alexis F. Guédon(Institut Pierre Louis d‘Épidémiologie et de Santé Publique), Sophie Georgin‐Lavialle(Sorbonne Université), Benjamin Terrier(Hôpital Cochin), David Saadoun(Sorbonne Université), J. Séguier(Aix-Marseille Université), M. Le Besnerais(Hôpital Charles-Nicolle), Claire de Moreuil(Centre Hospitalier Régional Universitaire de Brest), Guillaume Denis(Centre Hospitalier de Rochefort), Mathieu Gerfaud‐Valentin(Communauté urbaine de Lyon), Jean Sebastien Allain(Centre Hospitalier Universitaire de Rennes), Alexandre Maria(COMUE Languedoc-Roussillon Universités), Laurence Bouillet(Centre Hospitalier Universitaire de Grenoble), Vincent Grobost(Centre Hospitalier Universitaire de Clermont-Ferrand), J. Galland(Int'Air Medical (France)), Olivier Kosmider(Assistance Publique – Hôpitaux de Paris), Anaël Dumont(Centre Hospitalier Universitaire de Caen Normandie), Mathilde Devaux(Centre Hospitalier Intercommunal de Poissy), Benjamin Subran(Hôpital de la Croix-Rousse), Jean M. Schmidt(Centre Hospitalier Universitaire Amiens-Picardie), Paola Marianetti-Guingel(Centre Hospitalier Universitaire de Reims), Sylvain Audia(Inserm), S. Palat(Centre Hospitalier Universitaire de Limoges), Marielle Roux‐Sauvat(Université de Bourgogne), Vincent Jachiet(Sorbonne Université), Pierre Hirsch(Sorbonne Université), O. Fain(Sorbonne Université), A. Mékinian(Sorbonne Université)
RMD Open
July 1, 2022
Cited by 86Open Access
Full Text

Abstract

OBJECTIVE: A new adult-onset autoinflammatory syndrome has been described, named VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic). We aimed to compare the clinical characteristics, the laboratory features and the outcomes between idiopathic-relapsing polychondritis (I-RP) and VEXAS-relapsing polychondritis (VEXAS-RP). METHODS: Patients from French retrospective multicentre cohort of RP were separated into two groups: a VEXAS-RP and an I-RP. RESULTS: Compared with patients with I-RP (n=40), patients with VEXAS-RP (n=55) were men (96% vs 30%, p<0.001) and were older at diagnosis (66 vs 44 years, p<0.001). They had a greater prevalence of fever (60% vs 10%, p<0.001), of skin lesions (82% vs 20%, p<0.001), of ocular involvement (57% vs 28%, p=0.01), of pulmonary infiltrates (46% vs 0%, p<0.001), of heart involvement (11% vs 0%, p=0.0336) and with higher median C-reactive protein levels (64 mg/L vs 10 mg/L, p<0.001). Seventy-five per cent of the patients with VEXAS-RP had myelodysplastic syndrome (MDS) versus none in I-RP group. The glucocorticoids use, and the number of steroid sparing agents were similar in both groups, but patients with VEXAS-RP had more frequent refractory disease (remission obtained in 27% vs 90%, p<0001). VEXAS-RP was associated with higher risk of death: six patients (11%) died in the VEXAS-RP group after a median follow-up of 37 months and none in the I-RP group after a median follow-up of 92 months (p<0.05). CONCLUSION: We report the largest cohort of VEXAS-RP, characterised by high prevalence of male sex, fever, skin lesion, ocular involvement, pulmonary infiltration, heart involvement, older age and MDS association.


Related Papers

No related papers found

Powered by citation graph analysis